Baxter International
BAX
$23.35
+5.42%
Baxter International Inc. is a global healthcare company that manufactures and sells a broad portfolio of medical supplies and equipment, including injectable therapies, IV pumps, nutritional products, surgical sealants, and hospital beds, primarily serving hospitals and care providers. Following the acquisition of Hillrom in late 2021 and the divestiture of its kidney care business in early 2025, Baxter has refocused as a pure-play hospital products company, positioning itself as a diversified supplier with a strong competitive moat in essential medical consumables. The current investor narrative centers on Baxter's turnaround story, as the company navigates manufacturing disruptions, weak 2026 profit guidance, and margin pressures from rising petrochemical costs, while investors debate whether cost-cutting and portfolio simplification can restore growth and profitability.…
BAX
Baxter International
$23.35
Related headlines
BAX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Baxter International's 12-month outlook, with a consensus price target around $21.95 and implied upside of -6.0% versus the current price.
Average Target
$21.95
0 analysts
Implied Upside
-6.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $40
Analyst target range
Baxter is covered by 11 analysts, with a consensus recommendation of 'hold' (mean recommendation 2.85 on a 1-5 scale where 1 is strong buy). The distribution includes 2 buys (Evercore ISI Outperform, Barclays Overweight), 1 sell (Citigroup Sell), and the rest neutral. The average target price is $21.95, implying a slight downside of -0.9% from the current price of $22.15. The consensus leans neutral to slightly bearish, reflecting uncertainty about the turnaround. The target range spans from a low of $17.00 to a high of $40.00, indicating wide dispersion in analyst views. The high target of $40.00 implies 80.6% upside and likely assumes a successful restructuring, margin recovery, and multiple expansion. The low target of $17.00 implies -23.2% downside and prices in continued operational struggles, margin compression, and potential debt concerns. Recent rating actions show mixed signals: Citigroup downgraded from Neutral to Sell in May 2026, while Barclays and Evercore have maintained Overweight/Outperform ratings. The wide spread between high and low targets (23 points) signals high uncertainty, typical of a company in transition. The limited number of analysts (11) is consistent with a mid-cap stock that may not have deep institutional coverage, which can lead to less efficient price discovery and higher volatility.
Bulls vs Bears: BAX Investment Factors
Baxter presents a classic turnaround debate: deep value metrics (0.87x PS, 7.3% FCF yield) versus operational distress (negative margins, revenue deceleration, manufacturing disruptions). The bull case rests on the company's essential product portfolio and low valuation, while the bear case focuses on persistent unprofitability and near-term headwinds. Currently, the bearish evidence is stronger given the weak guidance and margin compression, but the stock's recent price momentum and low valuation suggest that much of the bad news is already priced in. The single most important tension is whether Baxter can return to sustainable profitability—if margins recover, the stock could re-rate significantly; if not, further downside toward the 52-week low of $15.73 is possible.
Bullish
- Deep Value at 0.87x PS: Baxter's price-to-sales ratio of 0.87x is a 65% discount to the industry median of ~2.5x, near its historical low. This suggests the market has priced in significant pessimism, offering a potential value opportunity if the turnaround succeeds.
- Recent Price Momentum Improving: The stock has rallied 22.1% over the past 3 months and 6.4% over the past month, outperforming the S&P 500 by 15.8% and 5.8% respectively. This technical strength could signal a trend reversal from the -21.6% one-year decline.
- Positive Free Cash Flow Generation: Baxter generated $714 million in TTM free cash flow, yielding 7.3% relative to its $9.8B market cap. This cash flow provides a cushion for debt service and restructuring investments, even amid GAAP losses.
- Essential Medical Supplier Moat: Baxter's portfolio of hospital consumables (IV pumps, injectables, surgical sealants) is mission-critical with high switching costs. The company serves a diversified base, reducing revenue concentration risk.
Bearish
- Unprofitable with Negative Net Margin: Baxter posted a net loss of $15 million in Q1 2026 and a TTM net margin of -8.5%. The company has been unprofitable in three of the last four quarters, with ROE at -15.6%, indicating poor capital allocation.
- Weak 2026 Guidance and Revenue Deceleration: Management's 2026 profit guidance fell below expectations, and Q1 2026 revenue growth slowed to 2.9% YoY from 8.0% in Q4 2025. This deceleration raises doubts about the company's ability to sustain momentum.
- Manufacturing and Supply Chain Disruptions: A manufacturing disruption has hit Baxter's cancer drug supply in Europe, and rising petrochemical costs from Strait of Hormuz tensions are expected to pressure margins. These operational headwinds could delay the turnaround.
- High Debt Load and Interest Burden: Debt-to-equity of 1.63x is elevated, and interest expense of $78 million in Q1 2026 consumed a significant portion of operating income ($66 million). This leverage amplifies earnings volatility and limits financial flexibility.
BAX Technical Analysis
Baxter's stock is in a sustained downtrend over the past year, with a 1-year price change of -21.59%, significantly underperforming the S&P 500's +20.92% gain. The current price of $22.15 sits at 46.5% of its 52-week range (low $15.73, high $29.35), indicating the stock is closer to its low than its high. This positioning suggests the market has priced in considerable pessimism, but the stock has not yet confirmed a reversal, as it remains well below its 52-week midpoint. Short-term momentum has improved markedly, with the 1-month price change of +6.44% and the 3-month change of +22.11%, contrasting sharply with the negative 1-year trend. This divergence could signal a potential trend reversal or a mean-reversion bounce, especially given the stock's beta of 0.613, which implies lower volatility than the market. However, the 1-month relative strength versus SPY is +5.84%, suggesting the recent rally is stock-specific and may be driven by short-covering or repositioning ahead of earnings. Key technical support lies near the 52-week low of $15.73, while resistance is at the 52-week high of $29.35. A breakout above $29.35 would signal a major trend reversal, while a breakdown below $15.73 could accelerate selling. With a beta of 0.613, Baxter is 38.7% less volatile than the S&P 500, meaning it offers relative stability but also less upside participation in broad market rallies.
Beta
0.61
0.61x market volatility
Max Drawdown
-49.7%
Largest decline past year
52-Week Range
$16-$29
Price range past year
Annual Return
-17.7%
Cumulative gain past year
| Period | BAX Return | S&P 500 |
|---|---|---|
| 1m | +14.1% | +0.1% |
| 3m | +24.8% | +5.7% |
| 6m | +16.1% | +8.5% |
| 1y | -17.7% | +20.3% |
| ytd | +19.7% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BAX Fundamental Analysis
Baxter's revenue trajectory shows modest growth, with Q1 2026 revenue of $2.701 billion, up 2.9% year-over-year from $2.625 billion in Q1 2025. However, the multi-quarter trend reveals deceleration: Q2 2025 revenue was $2.810 billion (+6.9% YoY), Q3 2025 was $2.835 billion (+5.1% YoY), and Q4 2025 was $2.974 billion (+8.0% YoY). The Q1 2026 growth rate of 2.9% is the slowest in recent quarters, signaling a potential slowdown. Revenue segments show Medical Products and Therapies as the largest at $1.285 billion, followed by Healthcare Systems and Technologies at $705 million and Pharmaceuticals at $621 million. The growth deceleration raises concerns about the company's ability to sustain momentum amid operational headwinds. Baxter is currently unprofitable on a GAAP basis, with a net loss of $15 million in Q1 2026, compared to net income of $126 million in Q1 2025. Gross margin improved to 32.99% in Q1 2026 from 32.8% in Q1 2025, but remains below the 38.2% level seen in Q2 2024, indicating margin compression. Operating margin was 2.44% in Q1 2026, down from 2.21% in Q1 2025 but recovering from negative territory in Q4 2025 (-24.5%). The net margin was -0.56%, a significant deterioration from +4.8% in Q1 2025. The trajectory toward profitability is uncertain, as the company has posted losses in three of the last four quarters. Baxter's balance sheet shows moderate leverage, with a debt-to-equity ratio of 1.63 and a current ratio of 2.31, indicating adequate short-term liquidity. Free cash flow (FCF) was $76 million in Q1 2026, down from $444 million in Q4 2025 but positive for the quarter. The FCF yield (FCF/market cap) is approximately 7.3% (using TTM FCF of $714 million and market cap of $9.803 billion), which is attractive but must be weighed against the company's debt load. ROE is negative at -15.6%, reflecting the net loss position, while ROA is 2.85%, suggesting asset efficiency is reasonable. The company generated $213 million in operating cash flow in Q1 2026, sufficient to cover capex of $137 million, but the reliance on debt (debt-to-equity of 1.63) indicates moderate financial risk.
Quarterly Revenue
$2.7B
2026-03
Revenue YoY Growth
+2.9%
YoY Comparison
Gross Margin
33.0%
Latest Quarter
Free Cash Flow
$714000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BAX Overvalued?
Since Baxter's net income is negative (TTM net loss), we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 0.87x, based on the current market cap of $9.803 billion and TTM revenue of approximately $11.24 billion. A forward PS is not directly available, but the low PS reflects the market's skepticism about Baxter's ability to generate sustainable profits. The EV/Sales multiple of 1.69x provides a more comprehensive view, incorporating debt. Compared to the industry average (Medical - Instruments & Supplies), Baxter's PS of 0.87x is at a significant discount; the industry median PS is approximately 2.5x, implying a 65% discount. This discount is likely justified by Baxter's negative net margins (-8.5% TTM) and declining profitability, whereas the industry typically enjoys positive margins. However, the low multiple could also present a value opportunity if the turnaround succeeds. Historically, Baxter's PS ratio has ranged from about 3x to 13x over the past five years. The current PS of 0.87x is near the bottom of its historical range, which was as high as 13.07x in mid-2021. This suggests the market is pricing in extremely pessimistic expectations, potentially overstating the downside risk if the company can stabilize earnings. The PB ratio of 1.60x is also near historical lows, further supporting the value thesis.
PE
-10.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 20x~45x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Baxter's primary financial risk is its inability to generate consistent profits. The company posted a TTM net loss of approximately $1.1 billion, with a net margin of -8.5%. Operating margin was just 2.4% in Q1 2026, barely covering interest expense of $78 million. The debt-to-equity ratio of 1.63x indicates moderate leverage, and with negative ROE (-15.6%), the company is destroying shareholder value. Free cash flow of $714 million TTM provides some buffer, but it is declining from $444 million in Q4 2025 to $76 million in Q1 2026. Revenue growth decelerated to 2.9% YoY in Q1 2026, the slowest in recent quarters, signaling potential demand weakness.
Market & Competitive Risks: Baxter's valuation at 0.87x PS is a deep discount to the industry median of 2.5x, but this discount is justified by its negative margins. If the turnaround fails, the stock could de-rate further toward the low analyst target of $17.00. The stock's beta of 0.613 suggests lower market correlation, but it has underperformed the S&P 500 by 42.5% over the past year. Competitive risks include pricing pressure from larger medical device peers and potential loss of market share if manufacturing disruptions persist. Recent news highlights rising petrochemical costs from geopolitical tensions, which could compress gross margins further from the current 33%.
Worst-Case Scenario: In a worst-case scenario, Baxter's manufacturing disruptions worsen, leading to product recalls or regulatory actions. Revenue growth turns negative, margins continue to compress, and the company breaches debt covenants, forcing a distressed restructuring. The stock could fall to the 52-week low of $15.73, representing a 29% decline from the current price of $22.15. If the broader market enters a recession, the low analyst target of $17.00 implies a 23% downside. Historical max drawdown of -49.68% suggests that in extreme cases, the stock could fall to approximately $11.15, though this is less likely given the essential nature of its products.